{Reference Type}: Journal Article
{Title}: Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities.
{Author}: Liu J;Wu X;Lin L;Pan H;Wang Y;Li Y;Zhao Y;Wang Z;
{Journal}: Mol Ther Oncolytics
{Volume}: 14
{Issue}: 0
{Year}: Sep 2019 27
{Factor}: 6.311
{DOI}: 10.1016/j.omto.2019.03.009
{Abstract}: Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes. Bispecific antibodies targeting Her2 have recently exhibited potent effects on Her2 signal inhibition. In this study, a novel biparatopic anti-Her2 bispecific antibody (Bp-Bs) was constructed by linking a single anti-CD3 Fab with two different anti-Her2 single-domain antibodies targeting non-overlapping epitopes of Her2. The Bp-Bs demonstrated strong binding on Her2-positive cells and potent cytotoxicity on Her2-positive tumor cells, even Her2-low expression cells, suggesting that biparatopic bispecific antibodies may have improved therapeutic benefits on broad Her2 patient populations.